PRCT vs. NVO
PRCT (PROCEPT BioRobotics Corporation) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — PRCT in Medical Devices, NVO in Drug Manufacturers - General. Over the past 3 years, PRCT returned -16.54%/yr vs -12.72%/yr for NVO. At a 0.19 correlation, their price movements are largely independent.
Performance
PRCT vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PRCT achieves a -32.55% return, which is significantly lower than NVO's 0.24% return.
PRCT
- 1D
- 1.58%
- 1M
- -17.45%
- 6M
- -32.27%
- YTD
- -32.55%
- 1Y
- -62.54%
- 3Y*
- -16.54%
- 5Y*
- —
- 10Y*
- —
NVO
- 1D
- -0.40%
- 1M
- 12.31%
- 6M
- -14.80%
- YTD
- 0.24%
- 1Y
- -25.17%
- 3Y*
- -12.72%
- 5Y*
- 4.73%
- 10Y*
- 8.21%
PRCT vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
PRCT PROCEPT BioRobotics Corporation | -32.55% | -60.93% | 92.13% | 0.89% | 66.09% | -28.54% |
NVO Novo Nordisk A/S | 0.24% | -39.22% | -15.93% | 54.84% | 22.66% | 11.97% |
Correlation
The correlation between PRCT and NVO is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (All Time) Calculated using the full available price history since Sep 15, 2021 | 0.19 |
Fundamentals
PRCT:
$1.21B
NVO:
$218.99B
PRCT:
-$2.76
NVO:
DKK 27.42
PRCT:
2.45
NVO:
4.39
PRCT:
$322.02M
NVO:
DKK 327.80B
PRCT:
$206.01M
NVO:
DKK 268.30B
PRCT:
-$90.33M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PRCT vs. NVO — Risk / Return Rank
PRCT
NVO
PRCT vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for PROCEPT BioRobotics Corporation (PRCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PRCT | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.51 | ||
| Sortino ratioReturn per unit of downside risk | -1.33 | ||
| Omega ratioGain probability vs. loss probability | 0.81 | 0.94 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | -0.93 | -0.51 | -0.42 |
| Martin ratioReturn relative to average drawdown | -1.28 | -0.80 | -0.49 |
Loading charts...
Drawdowns
PRCT vs. NVO - Drawdown Comparison
The maximum PRCT drawdown since its inception was -80.14%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for PRCT and NVO.
Loading charts...
Drawdown Indicators
| PRCT | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -80.14% | -74.70% | -5.44% |
Max Drawdown (1Y)Largest decline over 1 year | -67.12% | -49.17% | -17.95% |
Max Drawdown (3Y)Largest decline over 3 years | -80.14% | -74.70% | -5.44% |
Max Drawdown (5Y)Largest decline over 5 years | — | -74.70% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -78.66% | -64.19% | -14.47% |
Average DrawdownAverage peak-to-trough decline | -32.61% | -17.87% | -14.74% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 48.70% | 31.54% | +17.16% |
Volatility
PRCT vs. NVO - Volatility Comparison
PROCEPT BioRobotics Corporation (PRCT) has a higher volatility of 22.01% compared to Novo Nordisk A/S (NVO) at 8.73%. This indicates that PRCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PRCT | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.01% | 8.73% | +13.28% |
Volatility (6M)Calculated over the trailing 6-month period | 48.97% | 37.44% | +11.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 62.92% | 51.74% | +11.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 65.56% | 38.53% | +27.03% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 65.56% | 32.60% | +32.96% |
Dividends
PRCT vs. NVO - Dividend Comparison
PRCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.66%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 3.66% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
PRCT PROCEPT BioRobotics Corporation | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
PRCT vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between PROCEPT BioRobotics Corporation and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PRCT vs. NVO - Profitability Comparison
PRCT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, PROCEPT BioRobotics Corporation reported a gross profit of 53.95M and revenue of 83.13M. Therefore, the gross margin over that period was 64.9%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
PRCT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, PROCEPT BioRobotics Corporation reported an operating income of -32.61M and revenue of 83.13M, resulting in an operating margin of -39.2%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
PRCT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, PROCEPT BioRobotics Corporation reported a net income of -31.64M and revenue of 83.13M, resulting in a net margin of -38.1%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
PRCT and NVO have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PRCT has higher volatility (22.01%) compared to NVO (8.73%). In terms of maximum drawdown, PRCT dropped -80.14% vs NVO's -74.70%.
NVO currently has the higher Sharpe Ratio (-0.49 vs -1.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PRCT and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer